Scholarlink

<p>To evaluate the effect of morning or evening antihypertensive therapy on heart failure (HF), myocardial infarction, stroke and all-cause death in community resident patients in the TIME and BedMed trials, by study-level meta-analysis. These trials included 24,461 patients, experiencing 248 HFs, 371 myocardial infarctions, 331 strokes and 1,044 all-cause deaths. The pooled hazard ratio (HR) and 95% confidence interval (CI) between therapy groups were calculated for each event. For HF, myocardial infarction, stroke and all-cause death, the HRs (95%) CIs, P value, for evening versus morning therapy were 0.77 (0.60-0.99), <i>P</i> = 0.04, 1.02 (0.77–1.35), <i>P</i> = 0.91, 0.92 (0.74–1.14), <i>P</i> = 0.43, and 1.02 (0.90–1.14), <i>P</i> = 0.79, respectively. No heterogeneity was found for HF, stroke and all-cause death, and mild heterogeneity was observed for myocardial infarction. In the TIME and BedMed trials, compared to morning therapy, evening therapy was associated with a 23% lower risk of HF, whereas no difference was observed for other outcomes.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effect of morning or evening antihypertensive therapy on heart failure in community resident patients: Results of the TIME and BedMed Trials

  • 期刊论文

  • 发表日期：

    2025年12月10日

查看全文
  • Francesca Coccina,
  • Sante D. Pierdomenico

摘要

To evaluate the effect of morning or evening antihypertensive therapy on heart failure (HF), myocardial infarction, stroke and all-cause death in community resident patients in the TIME and BedMed trials, by study-level meta-analysis. These trials included 24,461 patients, experiencing 248 HFs, 371 myocardial infarctions, 331 strokes and 1,044 all-cause deaths. The pooled hazard ratio (HR) and 95% confidence interval (CI) between therapy groups were calculated for each event. For HF, myocardial infarction, stroke and all-cause death, the HRs (95%) CIs, P value, for evening versus morning therapy were 0.77 (0.60-0.99), P = 0.04, 1.02 (0.77–1.35), P = 0.91, 0.92 (0.74–1.14), P = 0.43, and 1.02 (0.90–1.14), P = 0.79, respectively. No heterogeneity was found for HF, stroke and all-cause death, and mild heterogeneity was observed for myocardial infarction. In the TIME and BedMed trials, compared to morning therapy, evening therapy was associated with a 23% lower risk of HF, whereas no difference was observed for other outcomes.